712515
O-(3-Carboxypropyl)-O′-[2-(3-mercaptopropionylamino)ethyl]-polyethylene glycol
Mw 3000
Sinónimos:
Polyethylene glycol, α-Mercapto-ω-carboxy-PEG
About This Item
Productos recomendados
![O-(3-Carboxypropyl)-O′-[2-(3-mercaptopropionylamino)ethyl]-polyethylene glycol Mw 5000](/deepweb/assets/sigmaaldrich/product/structures/271/277/d02536f0-83d7-4416-9cea-f6213e09fe85/640/d02536f0-83d7-4416-9cea-f6213e09fe85.png)
![(R)-1-{(RP)-2-[2-(Diphenylphosphino)phenyl]ferrocenyl}ethylbis[3,5-bis-(trifluoromethyl)phenyl]phosphine ≥97%](/deepweb/assets/sigmaaldrich/product/structures/185/002/97358faf-b2d8-4de5-9315-73b6a8b3ae26/640/97358faf-b2d8-4de5-9315-73b6a8b3ae26.png)
![O-[2-(3-Mercaptopropionylamino)ethyl]-O′-methylpolyethylene glycol 5,000](/deepweb/assets/sigmaaldrich/product/structures/293/792/95ae9557-6907-4575-8903-f5b87ada86e2/640/95ae9557-6907-4575-8903-f5b87ada86e2.png)
Formulario
powder
Nivel de calidad
mol peso
Mw 3000
idoneidad de la reacción
reagent type: cross-linking reagent
Ω-final
thiol
α-final
carboxylic acid
temp. de almacenamiento
−20°C
¿Está buscando productos similares? Visita Guía de comparación de productos
Categorías relacionadas
Envase
Código de clase de almacenamiento
11 - Combustible Solids
Clase de riesgo para el agua (WGK)
WGK 3
Punto de inflamabilidad (°F)
Not applicable
Punto de inflamabilidad (°C)
Not applicable
Equipo de protección personal
Eyeshields, Gloves, type N95 (US)
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Los clientes también vieron
Artículos
Circulatory half-life is a key success factor for new drugs. In this respect, PEGylation or PEG-ing—the modification of potential candidates ranging from non-peptidic small molecules to peptides and proteins, antibody fragments, aptamers, and saccharides or oligonucleotides with polyethylene glycol chains—offers numerous advantages.
Circulatory half-life is a key success factor for new drugs. In this respect, PEGylation or PEG-ing—the modification of potential candidates ranging from non-peptidic small molecules to peptides and proteins, antibody fragments, aptamers, and saccharides or oligonucleotides with polyethylene glycol chains—offers numerous advantages.
Circulatory half-life is a key success factor for new drugs. In this respect, PEGylation or PEG-ing—the modification of potential candidates ranging from non-peptidic small molecules to peptides and proteins, antibody fragments, aptamers, and saccharides or oligonucleotides with polyethylene glycol chains—offers numerous advantages.
Circulatory half-life is a key success factor for new drugs. In this respect, PEGylation or PEG-ing—the modification of potential candidates ranging from non-peptidic small molecules to peptides and proteins, antibody fragments, aptamers, and saccharides or oligonucleotides with polyethylene glycol chains—offers numerous advantages.
Protocolos
Science Slam panel: Leading gene therapy developers discuss commercialization challenges and the importance of robust process development plans.
Science Slam panel: Leading gene therapy developers discuss commercialization challenges and the importance of robust process development plans.
Science Slam panel: Leading gene therapy developers discuss commercialization challenges and the importance of robust process development plans.
Science Slam panel: Leading gene therapy developers discuss commercialization challenges and the importance of robust process development plans.
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico